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OBJECTIVES We compared American College of Cardiology/American Heart Association (ACC/AHA)
lesion classification with the recently proposed Mayo Clinic risk score to predict complica-
tions following percutaneous coronary intervention (PCI).
BACKGROUND The ability of the ACC/AHA classification system to predict complications following PCI
has been modest. With the inclusion of patient demographics, acuity of presentation, and
measure of left ventricular function, models with better discriminatory accuracy are presently
available.
METHODS The Mayo Clinic risk score is constructed by adding integer scores for the presence of eight
variables. We mapped the lesion-specific risk levels to a patient level by counting the number
of lesions in each class (A, B1, B2, C, and unknown).
RESULTS In 5,064 PCIs, 183 patients (4%) had the primary end point (death, Q-wave myocardial
infarction, stroke, emergency coronary artery bypass graft). Of the 7,632 treated lesions, 891
(12%) were unsuccessfully treated with PCI (residual stenosis 20%). The discriminatory
ability of the Mayo Clinic risk score model for prediction of the primary end point, as
measured by the c-statistic, was 0.78 (95% confidence interval [CI] 0.74 to 0.81). The Mayo
Clinic risk score offered significantly better risk stratification than the ACC/AHA lesion
classification counts (95% CI for c-statistic difference: 0.05 to 0.15). Regarding angiographic
success, the ACC/AHA lesion classification was a better system (95% CI for c-statistic
difference: 0.08 to 0.03 favoring ACC/AHA classification), although its absolute ability
was modest (c  0.58).
CONCLUSIONS Mayo Clinic risk score offers significantly better prediction for cardiovascular complications
than the ACC/AHA classification. However, lesion classification by ACC/AHA classifica-
tion is a better predictor for angiographic success. (J Am Coll Cardiol 2004;44:357–61)
© 2004 by the American College of Cardiology Foundationn
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the American College of Cardiology/American Heart As-
ociation (ACC/AHA) lesion classification scheme was
nitially proposed in 1986 (1) and subsequently modified in
990 (2). These classifications required evaluation of 11
ngiographic variables for each lesion and were introduced
o predict results based on the anticipated difficulty of the
equired percutaneous coronary intervention (PCI) proce-
ure. Major limitations of this classification scheme are
ubjective angiographic lesion assessment with considerable
nterobserver variability (3) and exclusion of important
atient (4,5), left ventricular function (5), and acuity of
resentation variables (6) that have considerable influence
n the outcome of a PCI procedure. We developed a risk
core comprising five clinical and three angiographic vari-
bles to predict death, Q-wave myocardial infarction (MI),
troke, and the need for emergency coronary artery bypass
raft surgery (CABG) (7). This model was initially inter-
From the *Division of Cardiovascular Diseases and Internal Medicine; and
Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, Minnesota.
Manuscript received January 8, 2004; revised manuscript received March 18, 2004,sccepted March 22, 2004.ally validated and more recently externally validated using
he National Heart, Lung, and Blood Institute (NHLBI)
ynamic Registry, with excellent discriminatory accuracy to
redict complications following percutaneous coronary pro-
edures. The information on the lesion complexity is rou-
inely recorded in the Mayo Clinic PCIs registry. The utility
f the ACC/AHA lesion classification score is not clear
ith the current advancement in the procedure techniques,
perator experience, and availability of stents. With this
ackground, we compared the discriminatory ability of the
ayo Clinic risk score with the ACC/AHA lesion classi-
cation for prediction of both complications and angio-
raphic failure.
ATERIALS AND METHODS
tudy population. There were 6,023 coronary angioplasty
rocedures performed on 5,193 unique patients at Saint
ary’s Hospital at Mayo Clinic from January 1, 2000,
hrough July 31, 2003; 129 patients refused to allow use of
heir records for research and hence were excluded. We
elected the earliest PCI from the remaining 5,064 patients
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pproved the study.
lassification measures. The Mayo Clinic risk score for
CI complications has been previously described (7). In
rief, this score is constructed by adding integer scores for
he presence of eight possible risk factors. Five variables are
atient/procedural characteristics: age, congestive heart fail-
re, New York Heart Association (NYHA) functional class
III, urgent/emergent PCI, chronic renal disease, and
reprocedural cardiogenic shock. The other three are related
o angiographic characteristics: left main stenosis 70%,
ultivessel disease (more than 70% in more than 1 major
picardial coronary artery, or in one of their major
ranches), and presence of thrombus in any lesion. Some
isk factors were unrecorded for some patients. In the
resence of missing data (10% for any component), the
isk was assumed to have not been present for calculation of
he score. The score was also grouped into five categories of
isk: very low, low, moderate, high, and very high.
The ACC/AHA lesion classification orders lesions into
our groups: A, B1, B2, and C. This classification scheme
as not adopted for patients presenting with acute MI, who
as therefore treated as not available. We mapped the
esion-specific risk levels to a patient level by two methods.
irst, we counted the number of lesions in each class (A, B1,
2, C, and unknown). Thus, five integer variables defined
he patient-level ACC/AHA classification. Second, we
imply recorded the worst lesion classification. Here, we had
our indicators for the worst lesion classification (A, B1, B2,
r C) plus an indicator for a missing measure on any lesions.
he first method contains more information, especially
egarding the number of lesions treated. The second
ethod is simple and commonly used.
rimary end point. The primary end point was post-PCI
n-hospital major adverse cardiac event (death, Q-wave MI,
mergency CABG, or stroke). The secondary end point was
esion-specific angiographic failure defined as residual ste-
osis 20% post-PCI.
tatistical analysis. Patient, procedural, and angiographic
haracteristics are summarized as mean  SD for continu-
us measures unless noted otherwise, and frequency (per-
entage) for discrete risk factors. The c-statistic (the area
Abbreviations and Acronyms
ACC  American College of Cardiology
AHA  American Heart Association
CABG  coronary artery bypass graft
CI  confidence interval
MACE  major adverse cardiovascular events
MI  myocardial infarction
NHLBI  National Heart, Lung, and Blood Institute
NYHA  New York Heart Association
PCI  percutaneous coronary intervention
SCAI  Society for Cardiac Angiography and
Interventionsnder the receiver operator curve) was used to estimate the biscriminatory ability of the risk stratification systems. This
eflects the classification system’s ability to correctly order
atients in sets of increasing risk. Angiographic failure is a
esion-specific end point; thus each lesion was an individual
bservation for the analysis of angiographic failure. The
ayo Clinic risk score was attributed to each lesion by
dding the patient-level risk integers as usual, but only
dding left main stenosis and thrombus to the relevant
esions. A total of 1,000 bootstrap samples were used to
stimate 95% confidence intervals for the c-statistics. Dif-
erences in the c-statistic for different classification systems
ere calculated for each bootstrap sample. Bootstrapping
or the angiographic failure end point, however, did not
esample individual lesions, but rather resampled each
atient to maintain the within-patient lesion correlations.
ESULTS
he primary end point of death, Q-wave MI, stroke, or
mergency CABG was seen in 183 patients (4%). Of the
,632 treated lesions, 891 (12%) were unsuccessfully treated
ith PCI (residual stenosis 20%). The patient character-
stics are listed in Table 1. The mean age was 66.9  12.0
ears. There were 19% of patients with MI within 24 h of
he procedure, 4% had cardiogenic shock, 66% had non-
lective PCI, 7% had NYHA functional class III or higher
eart failure, and 4% had moderate to severe renal disease.
he median Mayo Clinic risk score was 6. We divided the
atients into five risk groups based on the previous risk score
odel. Patients were considered very low risk to very high
isk depending upon the number of clinical and angio-
raphic variables present in a particular patient. There were
9% patients in the moderate-to-high risk group and 2%
able 1. Baseline and Procedural Variables
Variable
Overall
(n  5,064)
ge, yrs 66.9  12.0
ale, n (%) 3,540 (70%)
yocardial infarction 24 h, n (%) 955 (19%)
reprocedural shock, n (%) 213 (4%)
nstable angina, n (%) 2,817 (56%)
onelective PCI, n (%) 3,363 (66%)
iabetes, n (%) 1,257 (25%)
ypertension, n (%) 3,470 (72%)
istory of cholesterol 240, n (%) 3,813 (83%)
ongestive heart failure, n (%) 619 (12%)
YHA angina class III, n (%) 313 (7%)
urrent/former smoker, n (%) 3,236 (65%)
oderate/severe renal disease, n (%) 178 (4%)
ayo risk score, median (Q1, Q3) 6.0 (5.0, 8.0)
stimated risk group, n (%)
Very low (2%) 1,878 (37%)
Low (2%–4%) 2,139 (42%)
Moderate (5%–10%) 761 (15%)
High (10%–25%) 181 (4%)
Very high (25%) 105 (2%)
YHA New York Heart Association; PCI percutaneous coronary interventions.elonged to the very-high-risk group.
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July 21, 2004:357–61 Prediction of Complications After PCIsTable 2 summarizes the procedural and angiographic
ariables. Among these variables, 2% had significant left
ain disease, 52% had multivessel disease, and 30% had
ngiographic thrombus. Glycoprotein IIb/IIIa inhibitors
ere used in 63%. The ACC/AHA lesion type A was seen
n 4% of patients, types B1 and B2 in 52% of patients, and
ype C in 36% of patients. The lesion classification was not
vailable in 8% of patients.
Table 3 outlines the in-hospital complications. There
ere 86 deaths (1.7%), 67 Q-wave MI (1.3%), and 28
atients (0.6%) were referred for emergency CABG. An-
iographic failures were seen in 891 lesions (11.7%).
Table 4 demonstrates the increase in major adverse
ardiovascular events (MACE) with increasing Mayo Clinic
isk score, and also with worsening ACC/AHA lesion
lassification when all treated lesions are classified. The risk
ncreased from 1.1% for MACE in patients with a very low
ayo Clinic risk score to 33.3% in the very-high-risk
ategory. The risk for MACE in ACC/AHA type A and
1 lesion category was very low, and similar to Mayo Clinic
isk score for the very-low risk category; however, the
able 2. Lesion Characteristics of the Percutaneous
oronary Interventions
Variable
Overall
(n  7,632)
essel, n (%)
Left anterior descending 2,942 (39%)
Left circumflex 1,928 (25%)
Left main 96 (1%)
Right coronary artery 2,661 (35%)
CC/AHA lesion type, n (%)
A 287 (4%)
B1 1,527 (20%)
B2 2,432 (32%)
C 2,758 (36%)
Unknown 628 (8%)
efinite/probable thrombus, n (%) 1,669 (23%)
reprocedure % stenosis 85.9  12.3
ein graft treated, n (%) 474 (6%)
eft main 70% stenosis, n (%)* 76 (2%)
ultivessel disease (70/70), n (%)* 2,474 (52%)
hrombus in any lesion, n (%)* 1,423 (30%)
otal # of stents placed* 1.4  1.0
lycoprotein IIb/IIIa use, n (%)* 3,192 (63%)
Patient level variables.
ACC/AHA  American College of Cardiology/American Heart Association.
able 3. In-Hospital Major Adverse Cardiovascular Events
ollowing Percutaneous Coronary Intervention
Variable
Overall
(n  5064)
n-hospital death, n (%) 86 (1.7%)
n-hospital Q-wave MI, n (%) 67 (1.3%)
n-hospital emergency CABG, n (%) 28 (0.5%)
n-hospital stroke, n (%) 24 (0%)
n-hospital MACE, n (%) 183 (3.6%)
ngiographic failure, n (%)* 891 (11.7%)
Per treated lesion (n  7,632).
CABG  coronary artery bypass graft; MI  myocardial infarction; MACE ajor adverse cardiovascular events. CACE rates for ACC/AHA type B2 and C were 2.2% and
.9%, respectively. The risk when some lesion classes are
nknown is 8.0%.
Table 5 compares the discriminatory ability of the Mayo
linic risk score with the ACC/AHA lesion score. The
ayo integer score and group score gave similar results for
ACE prediction. The c-statistic for association with
ACE for the Mayo Clinic score was 0.78 (95% confi-
ence interval [CI]: 0.74 to 0.81). It was 0.77 (95% CI: 0.73
o 0.80) when the Mayo Clinic risk score was applied to
tratify patients into five groups of risk. This was signifi-
antly better than ACC/AHA lesion classification counts
c-statistic 0.67, 95% CI: 0.64 to 0.72) and c-statistic of
.66 (95% CI: 0.63 to 0.70) for worst lesion scheme, as the
5% confidence interval (0.05 to 0.15) for the difference in
-statistics did not include 0. The angiographic failure
rediction with ACC/AHA lesion classification was mod-
st. The c-statistic was 0.58 (95% CI: 0.56 to 0.60), which
as superior to the Mayo Clinic risk score (c-statistic 0.53;
5% CI: 0.50 to 0.55). The difference was statistically
ignificant (95% CI for difference: 0.08 to 0.03). We
lso tested this model using 50% residual stenosis as the
efinition for angiographic failure (data not shown). The
able 4. Major Adverse Cardiovascular Events Based on the
ayo Clinic Risk Score and ACC/AHA Lesion Score
Risk Class n # MACE Event Rate
ayo risk group
Very low 1,878 21 1.1%
Low 2,139 45 2.1%
Moderate 761 55 7.2%
High 181 27 14.9%
Very high 105 35 33.3%
CC/AHA worst lesion
All lesions classified
A 166 2 1.2%
B1 838 9 1.1%
B2 1,648 37 2.2%
C 1,899 94 4.9%
Some lesions unknown 513 41 8.0%
CC/AHA  American College of Cardiology/American Heart Association;
ACE  major adverse cardiac events.
able 5. Discriminatory Measures of Mayo Clinic and ACC/
HA Lesion Risk Scores
Risk Measure
Sample
c-Statistic
95% CI From
Bootstrapping
ACE prediction
(1) Mayo score 0.78 0.74, 0.81
(2) Mayo score grouping 0.77 0.73, 0.80
(3) ACC/AHA lesion counts 0.67 0.64, 0.72
(4) Worst ACC/AHA lesion 0.66 0.63, 0.70
(5) Difference: (1)  (3) 0.11 0.05, 0.15
(6) Difference: (2)  (3) 0.09 0.04, 0.14
ngiographic failure prediction
(1) Mayo score 0.53 0.50, 0.55
(2) ACC/AHA lesion class 0.58 0.56, 0.60
(3) Difference: (1)  (2) 0.05 0.08, 0.03I  confidence interval. Other abbreviations as in Table 4.
c
a
s
D
T
M
t
A
g
m
r
A
e
o
q
u
u
M
(
v
Q
e
6
A
f
p
a
c
w
m
c
l
S
0
s
s
o
c
s
T
p
r
T
(
e
g
u
w
(
l
f
A
f
p
(
c
a
v
i
a
v
p
T
a
o
A
f
m
t
a
m
t
o
o
e
f
a
o
m
f
(
c
p
s
f
v
a
v
w
i
d
n
v
i
c
L
s
fi
s
p
b
d
a
e
a
p
T
360 Singh et al. JACC Vol. 44, No. 2, 2004
Prediction of Complications After PCIs July 21, 2004:357–61onclusions are similar, with slightly better discriminatory
bility for both scores (Mayo score: c  0.55, ACC/AHA
core: c  0.65).
ISCUSSION
his study demonstrated that in the risk stratification for
ACE (death, Q-wave MI, stroke, emergency CABG),
he Mayo Clinic risk score fared significantly better than
CC/AHA lesion classification. For prediction of angio-
raphic failure, the ACC/AHA lesion classification has only
odest ability to stratify patients into increasing levels of
isk, but is superior to the Mayo Clinic risk score.
CC/AHA lesion classification. There has been a rapid
volution of percutaneous angioplasty techniques since the
riginal proposal of this classification in 1986 with subse-
uent modification in 1990 (1,2). It is still the most widely
sed system to assess patients’ risk from PCI, and is also
sed to scorecard the individual operator and the institution.
ore recently in a new classification system, two variables
non-chronic total occlusion and degenerated saphenous
ein grafts) were significantly correlated with death, non–
-wave MI, and the need for emergency CABG (8). Krone
t al. (9) applied the ACC/AHA lesion classification to
1,926 patients undergoing single-vessel angioplasty in the
CC-National Cardiovascular Data Registry (NCDR) and
ound ACC/AHA less accurate in predicting major com-
lications compared with Society for Cardiac Angiography
nd Interventions (SCAI) lesion classification. The
-statistic for major complications following PCI, however,
as modest (0.599 for original ACC/AHA, 0.624 for
odified ACC/AHA, and 0.665 for SCAI lesion classifi-
ation). On the other hand, the predictive accuracy of the
esion classification, whether assessed by ACC/AHA or
CAI classification, was better for lesion success (0.69,
.708, 0.75 for original, modified ACC/AHA lesion clas-
ification, and SCAI classification, respectively). In other
tudies, procedural success is adversely affected by presence
f type C lesions (10,11). Among the type C lesions,
hronic total occlusion and extreme tortuosity continue as
ignificant lesion variables affecting procedure outcome (12).
ype C lesion was also one of the significant variables
redictive of the need for emergency CABG (13). In a
ecent analysis of angiographic variables from the Do
irofiban and ReoPro Give Similar Efficacy Outcomes?
TARGET) trial, patients with a combination of lesion
ccentricity, lesion length 20 mm, and presence of angio-
raphic thrombus had 21.4% composite of death, MI, or
rgent target vessel revascularization at 30 days, compared
ith 4.2% in those patients without these high-risk features
14). High-risk patient subgroups, namely acute MI, shock,
eft main, and decompensated heart failure, were excluded
rom this study. In the risk adjustment model derived from
CC-NCDR from 1998 to 2000 for mortality prediction
ollowing PCI, significant difference were noted in patients
resenting with and without acute MI within 24 h of PCI t15). The worse SCAI lesion classification was significantly
orrelated with mortality in patients not presenting with
cute MI. In contrast, the correlation of these lesion
ariables was weak in patients presenting with acute MI.
The Mayo Clinic risk score was initially developed and
nternally validated from a combination of eight clinical and
ngiographic variables (7). More recently, it was externally
alidated in the NHLBI Dynamic Registry with excellent
rediction for in-hospital complications following PCI.
his risk score, whether applied as initially described or
pplied with patients stratified into different groups based
n the risk profile, fared significantly better than ACC/
HA lesion classification for prediction of complications
ollowing PCI. The disadvantages of the lesion score are its
odest predictive accuracy, poor interobserver correlation of
he variables, lack of demographic, left ventricular function,
cuity of presentation variables, improvement in the equip-
ent, operator experience, and stent techniques such that
he lesion variables currently may have lesser influence on
utcome. Also, lesion variables with varying results on the
utcomes are lumped together in the same category. For
xample, chronic total occlusion has higher angiographic
ailure rates than longer lesions (20 mm); however, both
re included in ACC/AHA type C category.
The current role of the lesion variables in the procedural
utcome after PCI is ill defined. The outcome is driven
ore by patient-related conditions (advancing age, renal
ailure, peripheral vascular disease), acuity of presentation
acute MI, shock), or angiographic or procedure-related
haracteristics (multivessel disease, intra-aortic balloon
ump use, thrombus) (6,16–18). A recent simplified scoring
ystem found four variables: age above 65 years, renal
ailure, multivessel disease, and MI 14 days. These four
ariables significantly predicted mortality following PCI,
nd none were lesion-related (19). The influence of lesion
ariables is more pronounced in elective cases and in studies
here MI was defined as elevation of biomarkers, as noted
n the study by Ellis et al. (8). Similar conclusions can be
rawn from other studies (14,15). Further studies are
eeded to develop modified risk scores that would integrate
ariables included in the Mayo Clinic risk score with the
nclusion of elevation of biomarkers as one of the major
omplications.
imitations. Experienced angiographers performed the as-
essment of lesion morphology; however, no core-lab con-
rmation was obtained. The fact that some lesions had
ome missing values for the ACC/AHA classification com-
licated the analysis, and the system may have fared slightly
etter if complete data were available. However, 10% of
ata were missing, and the unknown class is reflective of
ctual practice. Important postprocedure variables, such as
levation of cardiac biomarkers, were not included in the
nalysis. Significant elevation of these markers after a PCI
rocedure may have important prognostic implications (20).
he question of the applicability of the Mayo Clinic modelo non-referral, low-volume centers and to low-volume
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July 21, 2004:357–61 Prediction of Complications After PCIsnterventionists cannot be evaluated from the present study.
perative volume has been found to be significantly asso-
iated with adverse events following PCI (21–23). This
ariable was not addressed in the present study. Although
his report was accurate in predicting procedural complica-
ions, no predictive model can overcome the effect of chance
nd uncertainty inherent in invasive treatments.
onclusions. The present study demonstrated that the
urrent Mayo Clinic risk score has significantly better
iscriminatory ability to risk-stratify patients for complica-
ions following PCI than does the ACC/AHA lesion
lassification. Stratification by ACC/AHA class for angio-
raphic failure was modestly successful at best, but superior
o the Mayo Clinic risk score.
eprint requests and correspondence: Dr. Mandeep Singh, 200
nd Street SW, Mayo Clinic, Rochester, Minnesota 55905.
-mail: singh.mandeep@mayo.edu.
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